Actinium Pharmaceuticals (ATNM) Soars 24.05% on Clinical Program Success

On March 26, 2025, Actinium Pharmaceuticals (ATNM) saw a significant rise of 24.05% in pre-market trading, indicating strong investor interest and potential market opportunities.

Actinium Pharmaceuticals has been actively engaging with key opinion leaders (KOLs) and investors to highlight its revamped clinical programs and expanded market opportunities. The company recently hosted an investor call to discuss its newly initiated Actimab-A Solid Tumor Program, which has garnered significant attention.

The company has also announced a supply agreement with Eckert & Ziegler for the Ac-225 radioisotope, which will support its comprehensive development activities. This agreement is expected to enhance the company's ability to conduct clinical trials and bring new therapies to market.

Actinium Pharmaceuticals has entered into a research collaboration with Memorial Sloan Kettering to further expand the clinical applications of Actimab-A's backbone therapy strategy. This collaboration is aimed at leveraging the expertise of Memorial Sloan Kettering to advance the development of Actimab-A.

In addition, the company has announced a clinical trial program in solid tumors, combining Actimab-A with PD-1 checkpoint inhibitors KEYTRUDA and OPDIVO. This program is part of Actinium's broader strategy to explore the potential of its targeted radiotherapies in various cancer indications.

Actinium Pharmaceuticals has also published the results of the Actimab-A + CLAG-M trial in patients with relapsed or refractory acute myeloid leukemia in the peer-reviewed journal Leukemia. The positive results from this trial have further bolstered investor confidence in the company's pipeline.

Overall, Actinium Pharmaceuticals' recent activities and announcements have positioned the company as a leader in the development of targeted radiotherapies, with multiple potential blockbuster market opportunities on the horizon.